The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

Description of business:
Venn Life Sciences Holdings plc's wholly owned subsidiaries operate two types of business: - a CRO (Contract Research Organisation) business that provides clinical trial management and performance services, to pharmaceutical, medical device and biotechnology companies; and - a clinical resourcing business that supplies clinical staff to organisations that require additional resources. Venn provides services in a broad range of therapeutic areas, with a concentration of clinical experience in cardiology, neurology and oncology, as well as medical devices. Venn focuses on Phases II to IV of the clinical trial process, and presents itself to clients as a full service provider. Venn works with a wide range of clients, although revenue is concentrated towards large pharmaceutical companies. CRO Contracts typically have a value of between 250k and 500k, with contract periods ranging from two to ten years in the CRO business, and six to twelve months in the resourcing business. The Directors intend to expand the geographical footprint of the business across Europe through strategic acquisition combined with organic growth. Venn is open to considering co-development opportunities, particularly in the medical device arena. This would enable them to share in the revenue streams associated with intellectual property ownership and sale/licensing. Main Country of Operation: The Netherlands, with operations in Ireland, France and a branch office in Switzerland. Admission is being sought by way of a reverse takeover of an ISDX listed company (Armscote Investment Company Plc).

Back

Venn Life Sciences Holdings plc

Related links

Further informations about 7 and 7/30 days issues can be find by clicking on one of the options below:

Issues last 7 days

Last issues 7/30 days

Back to New and recent issues - Home



The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds